Maze Therapeutics (NASDAQ:MAZE) Shares Climb 5.5% – Here’s Why

Maze Therapeutics, Inc. (NASDAQ:MAZE) shot up 5.5% during mid-day trading on Monday. The company traded as high as $28.49 and last traded at $29.0450. Approximately 122,329 shares changed hands during trading, a decline of 82% from the average session volume of 670,087 shares. The stock had previously closed at $27.53.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on MAZE shares. Wall Street Zen lowered shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Canaccord Genuity Group initiated coverage on Maze Therapeutics in a research note on Monday. They set a “buy” rating and a $75.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Maze Therapeutics in a report on Monday, September 21st. Wedbush reissued an “outperform” rating and issued a $48.00 price objective on shares of Maze Therapeutics in a research note on Wednesday, September 23rd. Finally, BTIG Research restated a “buy” rating and issued a $46.00 target price on shares of Maze Therapeutics in a report on Tuesday, September 22nd. Three equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $64.45.

Maze Therapeutics Stock Up 5.6%

The company has a current ratio of 18.31, a quick ratio of 18.31 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $1.61 billion, a PE ratio of -11.59 and a beta of 2.16. The stock’s fifty day simple moving average is $26.76 and its 200-day simple moving average is $27.01.

Maze Therapeutics (NASDAQ:MAZE) last announced its earnings results on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, meeting the consensus estimate of ($0.76). As a group, sell-side analysts forecast that Maze Therapeutics, Inc. will post -2.70 EPS for the current fiscal year.

Insider Activity

In related news, CEO Jason V. Coloma sold 34,501 shares of the stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $27.02, for a total transaction of $932,217.02. Following the completion of the sale, the chief executive officer directly owned 15,558 shares of the company’s stock, valued at approximately $420,377.16. This trade represents a 68.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Courtney Phillips sold 2,012 shares of Maze Therapeutics stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $26.01, for a total value of $52,332.12. Following the sale, the insider owned 7,007 shares in the company, valued at $182,252.07. This trade represents a 22.31% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 192,991 shares of company stock valued at $5,152,084. 5.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Maze Therapeutics

Large investors have recently made changes to their positions in the business. Frazier Life Sciences Management L.P. raised its stake in shares of Maze Therapeutics by 10.2% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock worth $150,182,000 after purchasing an additional 465,641 shares during the period. TRV GP IV LLC purchased a new position in shares of Maze Therapeutics in the 2nd quarter worth about $133,502,907. ARCH Venture Management LLC bought a new position in Maze Therapeutics during the second quarter valued at about $122,983,582. BlackRock Inc. bought a new position in Maze Therapeutics during the second quarter valued at about $104,525,000. Finally, Jupiter Topco LLC bought a new position in Maze Therapeutics during the second quarter valued at about $101,764,000.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetic diseases. The company uses human genetics and its Maze Compass platform to identify disease-causing biological mechanisms and design small-molecule therapies intended to address the underlying drivers of disease.

Maze’s pipeline includes MZE001, an investigational oral therapy designed to inhibit glycogen synthase as a potential treatment for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles.